230 related articles for article (PubMed ID: 33388575)
1. Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities.
Orner EP; Rodgers MA; Hock K; Tang MS; Taylor R; Gardiner M; Olivo A; Fox A; Prostko J; Cloherty G; Farnsworth CW
Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115300. PubMed ID: 33388575
[TBL] [Abstract][Full Text] [Related]
2. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
Al-Mughales JA; Al-Mughales TJ; Saadah OI
Front Immunol; 2021; 12():705441. PubMed ID: 34539635
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect.
Maine GN; Lao KM; Krishnan SM; Afolayan-Oloye O; Fatemi S; Kumar S; VanHorn L; Hurand A; Sykes E; Sun Q
J Clin Virol; 2020 Dec; 133():104663. PubMed ID: 33161369
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays.
Harley K; Gunsolus IL
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 33106364
[TBL] [Abstract][Full Text] [Related]
5. Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course.
Higgins V; Fabros A; Wang XY; Bhandari M; Daghfal DJ; Kulasingam V
Clin Biochem; 2021 Apr; 90():1-7. PubMed ID: 33476578
[TBL] [Abstract][Full Text] [Related]
6. Back to normal; serological testing for COVID-19 diagnosis unveils missed infections.
Tsuchida T; Nitahara Y; Suzuki S; Komase Y; Candray K; Kido Y; Nakagama Y; Yamasaki Y; Imamura M; Kawahata K; Kunishima H; Fujitani S; Mineshita M; Matsuda T
J Med Virol; 2021 Jul; 93(7):4549-4552. PubMed ID: 33739483
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.
Suhandynata RT; Hoffman MA; Kelner MJ; McLawhon RW; Reed SL; Fitzgerald RL
J Appl Lab Med; 2020 Sep; 5(5):908-920. PubMed ID: 32428207
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.
Zhou C; Bu G; Sun Y; Ren C; Qu M; Gao Y; Zhu Y; Wang L; Sun L; Liu Y
J Med Virol; 2021 May; 93(5):2857-2866. PubMed ID: 33331654
[TBL] [Abstract][Full Text] [Related]
9. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
Shu H; Wang S; Ruan S; Wang Y; Zhang J; Yuan Y; Liu H; Wu Y; Li R; Pan S; Ouyang Y; Yuan S; Zhou P; Shang Y
Virol Sin; 2020 Dec; 35(6):744-751. PubMed ID: 32720214
[TBL] [Abstract][Full Text] [Related]
10. A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay.
Batra R; Olivieri LG; Rubin D; Vallari A; Pearce S; Olivo A; Prostko J; Nebbia G; Douthwaite S; Rodgers M; Cloherty G
J Clin Virol; 2020 Nov; 132():104645. PubMed ID: 32961429
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of five widely used serologic assays for antibodies to SARS-CoV-2.
Stocking C; de Miguel L; Suteu G; Dressel A; Soricelli A; Roskos M; Valor S; Mutschmann C; März W
Diagn Microbiol Infect Dis; 2022 Feb; 102(2):115587. PubMed ID: 34826767
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Longitudinal Evaluation of Six Commercial Immunoassays for the Detection of IgM and IgG Antibodies against SARS CoV-2.
Nedelcu I; Jipa R; Vasilescu R; Băicuș C; Popescu CI; Manea E; Stoichițoiu LE; Pinte L; Damalan A; Simulescu O; Stoica I; Stoica M; Hristea A
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206895
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay.
Higgins RL; Rawlings SA; Case J; Lee FY; Chan CW; Barrick B; Burger ZC; Yeo KJ; Marrinucci D
PLoS One; 2021; 16(3):e0247797. PubMed ID: 33661960
[TBL] [Abstract][Full Text] [Related]
15. Serological assay for anti-SARS-CoV-2 antibodies improves sensitivity of diagnosis of COVID-19 patients.
Rostamzadeh D; Mortezagholi S; Alinejad M; Jooya SR; Eskandarian M; Metvaei A; Vafaei S; Aboulghasemi H; Younesi V; Shabani M
Med Microbiol Immunol; 2021 Dec; 210(5-6):283-289. PubMed ID: 34564742
[TBL] [Abstract][Full Text] [Related]
16. Validation and performance comparison of three SARS-CoV-2 antibody assays.
Paiva KJ; Grisson RD; Chan PA; Huard RC; Caliendo AM; Lonks JR; King E; Tang EW; Pytel-Parenteau DL; Nam GH; Yakirevich E; Lu S
J Med Virol; 2021 Feb; 93(2):916-923. PubMed ID: 32710669
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point-of-Care Testing.
Conklin SE; Martin K; Manabe YC; Schmidt HA; Miller J; Keruly M; Klock E; Kirby CS; Baker OR; Fernandez RE; Eby YJ; Hardick J; Shaw-Saliba K; Rothman RE; Caturegli PP; Redd AD; Tobian AAR; Bloch EM; Larman HB; Quinn TC; Clarke W; Laeyendecker O
J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33208477
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
[TBL] [Abstract][Full Text] [Related]
20. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
